Commentary: Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor
Author:
Open Access
- 22 November 2016
- journal article
- editorial
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 7, 431
Abstract
Commentary: Overcoming mTOR resistance mutations with a new-generation mTOR inhibitorKeywords
Funding Information
- Wellcome Trust (095317/Z/11/Z)
This publication has 15 references indexed in Scilit:
- Overcoming mTOR resistance mutations with a new-generation mTOR inhibitorNature, 2016
- A Diverse Array of Cancer-Associated MTOR Mutations Are Hyperactivating and Can Predict Rapamycin SensitivityCancer Discovery, 2014
- mTOR Signaling in Growth Control and DiseaseCell, 2012
- Rapamycin passes the torch: a new generation of mTOR inhibitorsNature Reviews Drug Discovery, 2011
- Activating mutations of TOR (target of rapamycin)Genes to Cells, 2011
- New Inhibitors of the PI3K-Akt-mTOR Pathway: Insights into mTOR Signaling from a New Generation of Tor Kinase Domain Inhibitors (TORKinibs)2010
- The Pharmacology of mTOR InhibitionScience Signaling, 2009
- An ATP-competitive Mammalian Target of Rapamycin Inhibitor Reveals Rapamycin-resistant Functions of mTORC1Journal of Biological Chemistry, 2009
- Common corruption of the mTOR signaling network in human tumorsOncogene, 2008
- Targeting the mTOR signaling network in cancerTrends in Molecular Medicine, 2007